Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 116 Stomach Neoplasms 21 HER2-positive Breast Cancer 14 Neoplasms 12 Neoplasm Metastasis 12 Colorectal Neoplasms 11 Esophageal Neoplasms 9 Triple Negative Breast Neoplasms 5 Lung Neoplasms 5 Colonic Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Brain Neoplasms 5 Rectal Neoplasms 4 Ovarian Neoplasms 4 Meningeal Neoplasms 4 Endometrial Neoplasms 4 Biliary Tract Neoplasms 4 Adenocarcinoma Of Esophagus 4 Uterine Cervical Neoplasms 3 Salivary Gland Neoplasms 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Multiple Myeloma 3 Meningeal Carcinomatosis 3 Lymphoma, Non-Hodgkin 3 Inflammatory Breast Neoplasms 3 Hematologic Neoplasms 3 Gallbladder Neoplasms 3 Breast Diseases 3 Anatomic Stage I Breast Cancer AJCC v8 3

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Cancer Related Cognitive Decline × Trastuzumab × 1 year × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡